Bio X Cell社
Bio X Cell社(アメリカ)の目標は、高品質な抗体を安価な価格で供給し、優れたカスタマーサービスを提供することで、科学的な発見やイノベーションの前進を促すことです。そのために同社は、in vivoの前臨床試験に必要とされる超高純度かつ防腐剤・安定剤不使用で低エンドトキシの抗体を、既知の抗原と新規性の高い抗原に対して多数取り揃えています。
Bio X Cell社の抗体は:
低エンドトキシン|保存料およびキャリアタンパク質不使用|マウス病原体スクリーニング済み(InVivoPlus)|タンパク凝集物≤5%
弊社はBio X Cell社の正規代理店です。
大学および公的機関のお客様にはアカデミックディスカウントが適用されますので、お問い合わせください。
トピックス
ケモカイン軸標的分子(in vivo 研究用)
再現性の高いがん研究を支える、確かな設計
トランスレーショナル腫瘍生物学研究のための機能性抗体

Bio X Cellの機能性抗体は、In Vivoがん研究向けに設計されており、超高純度のキャリアフリー製剤と極めて低いエンドトキシンレベルにより、腫瘍モデルにおけるクリーンで再現性の高い免疫調節をサポートします。
がん研究における機能性抗体の重要性
- ・腫瘍生物学: 超低エンドトキシンにより、意図しないサイトカイン誘導・非特異的応答を排除します
- ・生体内環境で優れたパフォーマンスを発揮: in vivo における機能活性を実証済み
- ・一貫した実験結果を実現: あらゆる腫瘍モデルと試験デザインに対応し、再現性の高い確かなデータを実現します
- ・大規模な研究でも信頼される品質: 約30,000件の査読済み論文で引用
抗体の作用

InVivoMAb anti-mouse CD73
腫瘍微小環境において、CD73を介したアデノシンシグナル伝達が抗腫瘍免疫をどのように抑制するかを解明。免疫抑制機構や腫瘍生物学の再現性の高い研究に向けた、高品位な抗CD73抗体ラインアップをご覧ください。
今週注目の二重特異性抗体・免疫活性化ターゲット


in vivo 試験に必須のアイソタイプコントロール
真のシグナルと非特異的バックグラウンドを厳格に分離するネガティブコントロールにより、ブレのない高精度なデータ取得を実現します。
- ・超高純度・低エンドトキシン
- ・防腐剤・安定剤不使用
- ・In Vivoでの使用に対応
- ・3つの製品グレード:InVivoMAb™・InVivoPlus™・RecombiMAb™
InVivoPure™ 希釈バッファー
In Vivoおよび高度な研究モデル向けに設計され、最高水準の品質を実現します。
- ・超高純度・低エンドトキシン
- ・病原体スクリーニング済み
- ・動物モデルで安全性試験済み
- ・Bio X Cell抗体に最適化された組成およびpH
脳オルガノイド研究のさらなる進展へ
専門家の視点
Duke大学医学部 分子遺伝学・微生物学/細胞生物学/神経生物学分野のDr.Debby Silverは、従来の動物モデル単独では捉えきれなかったヒト神経発生プロセスの解明において、脳オルガノイドモデルが極めて有用である点を強調しています。こうした三次元培養系を取り入れることで、実験デザインがより強固になり、得られる生物学的解釈の確からしさと信頼性を大幅に高めることができます。

要点:
- ・3D構造により、ヒト固有の生物学的特徴・応答を忠実に維持
- ・脳オルガノイドの活用により、ヒト特異的な神経発生メカニズムの解明へ
- ・動物モデルとオルガノイドの相乗効果がもたらす、強固なトランスレーショナルリサーチ
抗体の作用

InVivoMAb 抗マウス PD-1 (CD279) モノクローナル抗体
InVivoMAb™ 抗マウスPD-1抗体は、PD-L1陽性オルガノイドに対して、T細胞がいつ、どのような理由で腫瘍細胞傷害活性を回復するのかを明らかにするのに役立ちます。オルガノイドを用いた免疫学研究で検証済みのPD-1抗体をご覧ください。
Bio X Cell 新着製品・最新情報
生体内(In Vivo)およびオルガノイドモデル間における、一貫した抗体性能の実証
Bio X Cellは、同社の機能性抗体がマウスin vivoモデルとヒト生体関連性の高いオルガノイドシステムの両方において一貫した性能を維持することを実証した、新たな査読付き論文の知見を発表しました。これにより研究者は、実験プラットフォームが異なっても試薬を再調製(リフォーミュレーション)することなく、同一の試薬をシームレスに使用できるようになります。
今注目の抗体ターゲット
Bio X Cell、東南アジア地域における正規販売代理店としてProBioscience Technologies社を指名
ProBioscienceとの提携により、Bio X Cellは、シンガポール、マレーシア、タイ、ベトナム、インドネシアで拡大する免疫学およびがん研究コミュニティへの販売網を強化します。ProBioscience Technologiesは、In Vivo研究向けに製剤化された超高純度・低エンドトキシンの機能性抗体をはじめとする、Bio X Cellの全製品ポートフォリオを現地で直接提供します。
Bio X Cell 新着製品・最新情報
がん免疫調節におけるチェックポイント阻害、免疫逃避、そしてその先へ
本ウェビナーでは、Dr.Gordon Freemanが、PD-1阻害抗体を用いて免疫チェックポイントの生物学的機構を解析し、前臨床モデルにおける治療メカニズムを検証する方法について解説します。
シグナルかノイズか? In Vivo CAR-Tを読み解く
In Vivo CAR-T研究が急速に進展する中、トランスレーショナル研究において生物学的シグナルを明確に捉えることの重要性がますます高まっています。In Vivo CAR-T研究において、研究者がどのように結果の解釈性向上に取り組んでいるのかをご紹介します。
Bio X Cell、オルガノイドで検証済みの機能性抗体を発表
Bio X Cell、オルガノイドで検証済みの機能性抗体によりトランスレーショナル研究の継続性を向上
Bio X Cellは、同一の機能性抗体を再調製することなく、マウスin vivoモデルとヒト生体関連性の高いオルガノイドシステムの両方において一貫した性能を発揮することを実証した、新たな査読付き論文のエビデンスを発表しました。
低エンドトキシンレベルの超高純度・キャリアフリー製剤により、感度の高い3D培養系におけるサイトカイン由来のアーティファクトを最小限に抑え、異なる実験系において再現性の高いブロッキング、細胞除去、活性化、中和を可能にします。
「In Vivoモデルとオルガノイドモデルで同一の抗体を使用することで、研究者はばらつきを低減し、研究間でより一貫性のある結果の解釈が可能になる」と、Bio X CellのCEO、Christopher Conway氏は述べています。
科学研究における再現性の向上を支援するため、Bio X Cellはフレデリック国立がん研究所(FNLCR)がフッド大学と共同で開催する2026 Reproducibility in Science Symposiumに協賛いたします。本シンポジウムにおいて、Bio X Cellは再現性の高い前臨床研究を支えるスケーラブルな組換え抗体製造プラットフォームに焦点を当てた学術ポスター発表を行います。
Bio X Cell社製品を用いた研究のご紹介
Publication Spotlight | Bio X Cell BE0101 in Action: IL-16 Remodels the Tumor Immune Microenvironment and Boosts Immunotherapy Efficacy
Hot Immunotherapy Target: OX40
In Vivo Depletion of Mouse Neutrophils Using Anti-Ly6G Antibodies
CD16CD32 for Fc receptor blocking
ウイルス感染の間、TIGITは免疫病変(immunopathology)を制限します
乳癌の転移を阻止する:カテプシンC阻害剤の役割
Cold TumorをHotに変える:乳がんに対する免疫の調節因子としてのRANK経路
LinkRNA EPIC1が免疫療法耐性獲得を仲介する
アルツハイマー病におけるApoE4毒性の新規モデル
COVID-19の発症と治療の新規モデル
腸内細菌叢を介した鎌状赤血球症とストレスのつながり
動き回るマクロファージ:肺胞マクロファージのパトロールの可視化
粘膜微小環境の問題―ウイルス素因における好中球性炎症の役割
新規チェックポイント阻害剤の抗NKG2A抗体は、T細胞およびNK細胞の両方の抗腫瘍免疫応答を促進する作用を持つ
微生物感染は自己免疫応答を誘導する
抗CD47抗体は循環器疾患の予防に有効である
免疫チェックポイント分子LAG-3に対する新たなリガンドFGL1の発見と、FGL1阻害によるT細胞の抗腫瘍免疫応答の可能性
癌の肺転移においてT細胞の酸素感知が果たす役割
悪性黒色腫はIFNγ変異を起こすことにより抗CTLA-4免疫療法に対抗する
ILC2に発現しているGITRの活性化は2型糖尿病を改善する
TNF阻害剤による予防的治療は多併用免疫療法の転帰を改善する可能性がある
がん免疫療法に最適化されたアゴニスト活性をもつ抗4-1BB抗体の探究
新着情報
2024.12.24更新分
| Cat. No. | Product Name | Clone |
|---|---|---|
| BE0442 | InVivoMAb anti-rat CD86 (B7-2) | OX-48 |
| BE0443 | InVivoMAb anti-mouse PDGFRα (CD140a) | APA5 |
| BE0444 | InVivoMAb anti-human/mouse/rat/canine/swine PSMA | 3F11 |
| BE0445 | InVivoMAb anti-mouse CD44 | KM703 |
| BE0446 | InVivoMAb anti-rat CD47 | OX-101 |
| BE0447 | InVivoMAb anti-mouse TREM-2 | 178 |
| BE0448 | InVivoMAb anti-rat CD90/mouse CD90.1 (Thy1.1) | OX-7 |
| BE0449 | InVivoMAb anti-mouse CCL5 (RANTES) | R6G9 |
| BE0450 | InVivoMAb anti-mouse CXCL16 (SR-PSOX) | 12-81 |
| CP178 | RecombiMAb anti-mouse PD-1 (CD279) | 29F.1A12™-CP178 |
| CP182 | RecombiMAb anti-mouse PD-1 (CD279) | RMP1-14-CP182 |
| CP186 | RecombiMAb Armenian hamster IgG1 isotype control, anti-hen egg lysozyme | N/A |
| CP188 | RecombiMAb rat IgG2a isotype control, anti-hen egg lysozyme | N/A |
| CP189 | RecombiMAb mouse IgG1 isotype control, anti-hen egg lysozyme | N/A |
| CP190 | RecombiMAb mouse IgG2a isotype control, anti-hen egg lysozyme | N/A |
| CP191 | RecombiMAb mouse IgG2b isotype control, anti-hen egg lysozyme | N/A |
| SIM0039 | InVivoSIM anti-human CEACAM5 (Labetuzumab Biosimilar) | Labetuzumab |
| SIM0040 | InVivoSIM anti-human mesothelin (Amatuximab Biosimilar) | Amatuximab |
| SIM0041 | InVivoSIM anti-human SLAMF7 (Elotuzumab Biosimilar) | Elotuzumab |
| SIM0042 | InVivoSIM anti-human IL-13 (Tralokinumab Biosimilar) | Tralokinumab |
| SIM0043 | InVivoSIM anti-human TIM-3 (Sabatolimab Biosimilar) | Sabatolimab |
| SIM0044 | InVivoSIM anti-human IL-1β (Canakinumab Biosimilar) | Canakinumab |
| SIM0045 | InVivoSIM anti-human CD326 (EpCAM) (Edrecolomab Biosimilar) | Edrecolomab |
| SIM0046 | InVivoSIM anti-human CTLA-4 (Tremelimumab Biosimilar) | Tremelimumab |
| SIM0047 | InVivoSIM anti-human amyloid-beta (Solanezumab Biosimilar) | Solanezumab |
| SIM0048 | InVivoSIM anti-human amyloid beta (Donanemab Biosimilar) | Donanemab |
| SIM0049 | InVivoSIM anti-human IL-1β (Gevokizumab Biosimilar) | Gevokizumab |
| SIM0050 | InVivoSIM anti-human EGFR (Panitumumab Biosimilar) | Panitumumab |
| SIM0051 | InVivoSIM anti-human TROP-2 (Sacituzumab Biosimilar) | Sacituzumab |
PD-1とPD-L1の結合を阻害するRecombiMAb anti-mouse PD-1 (CD279)
新商品のリコンビナント抗マウスPD-1(CD279)抗体(RMP1-14クローン)は、PD-1とそのリガンドであるPD-L1、PD-L2の結合を阻害するブロッキング抗体として機能します。RMP1-14クローンは、がんや自己免疫疾患のマウスモデルにおけるPD-1の機能の研究に特に有用です。マウスのPD-1を特異的にターゲティングし、様々な前臨床モデルで強力な抗腫瘍活性を示します。
2024.05.30更新分
| Cat. No. | Product Name | Clone |
|---|---|---|
| BE0423 | InVivoMAb anti-mouse VISTA | 8G8 |
| BE0424 | InVivoMAb anti-rat CTLA-4 (CD152) | WKH203 |
| BE0425 | InVivoMAb rat IgG2b isotype control, anti-trinitrophenol-keyhole limpet hemocyanin | TNP-4G1 |
| BE0426 | InVivoMAb anti-mouse Dendritic Cell Marker (33D1) | 33D1 |
| BE0427 | InVivoMAb anti-West Nile virus NS1 | 10NS1 |
| BE0428 | InVivoMAb anti-mouse CD11b | 5C6 |
| BE0429 | InVivoMAb anti-WNV E protein DIII-LR | E16 |
| BE0430 | InVivoMAb anti-WNV E protein DI-DII | E53 |
| BE0431 | InVivoMAb anti-Zika virus E protein DIII-LR | ZV-67 |
| BE0432 | InVivoMAb anti-Dengue virus type 2 E protein DIII | DV2-96 |
| BE0433 | InVivoMAb anti-Eastern equine encephalitis virus E2 protein | EEEV-3 |
| BE0434 | InVivoMAb anti-Powassan virus E protein | POWV-63 |
| BE0435 | InVivoMAb anti-Venezuelan equine encephalitis virus E2 protein | VEEV-57 |
| BE0436 | InVivoMAb anti-human VISTA | GG8 |
| BE0437 | InVivoMAb anti-Dengue virus type 4 E protein DIII | DV4-E88 |
| BE0438 | InVivoMAb anti-SARS-CoV-2 S protein (RBD) | SARS2-38 |
| BE0439 | InVivoMAb anti-rat CD4 | W3/25 |
| CP158 | RecombiMAb anti-mouse PD-L1 (B7-H1) | 10F.9G2™-CP158 |
| SIM0033 | InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar) | Tiragolumab |
| SIM0034 | InVivoSIM anti-human CD38 (Daratumumab Biosimilar) | Daratumumab |
2024.03.22更新分
| Cat. No. | Product Name | Clone |
|---|---|---|
| BE0415 | InVivoMAb anti-rat CD8α | OX-8 |
| BE0416 | InVivoMAb anti-human/mouse GRP78 | N88 |
| BE0417 | InVivoMAb anti-rat CD2 | OX-34 |
| BE0418 | InVivoMAb anti-rat CD28 | JJ316 |
| BE0419 | InVivoMAb anti-rat IL-4 | OX-81 |
| BE0420 | InVivoMAb anti-mouse CD205 (DEC-205) | NLDC-145 |
| BE0421 | InVivoMAb anti-chikungunya virus E2 | CHK-265 |
| BE0422 | InVivoMAb anti-mouse CD86 (B7-2) | 2D10 |
| CP172 | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | RB6-8C5-CP172 |
| CP175 | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme | N/A |
| SIM0032 | InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) | Lecanemab |
BioXCell社の抗体は、国内外の大学、製薬企業等で幅広くご使用いただいております。
商品詳細や価格等は東京未来スタイルまでお問い合わせください。
| ランク | カタログ番号 | クローン | 商品名 |
|---|---|---|---|
| 1 | BE0146 | RMP1-14 | InVivoMab anti-mouse PD-1 (CD279) |
| 2 | BE0089 | 2A3 | InVivoMab rat IgG2a isotype control, anti-trinitrophenol |
| 3 | BP0146 | RMP1-14 | InVivoPlus anti-mouse PD-1 (CD279) |
| 4 | BE0101 | 10F.9G2 | InVivoMab anti-mouse PD-L1 (B7-H1) |
| 5 | BE0090 | LTF-2 | InVivoMab rat IgG2b isotype control, anti-keyhole limpet hemocyanin |
| 6 | BP0089 | 2A3 | InVivoPlus anti-mouse CTLA-4 (CD152) |
| 7 | BE0003-1 | GK1.5 | InVivoMab anti-mouse CD4 |
| 8 | BE0131 | 9H10 | InVivoMab anti-mouse CTLA-4 (CD152) |
| 9 | BP0101 | 10F.9G2 | InVivoPlus anti-mouse PD-L1 (B7-H1) |
| 10 | BE0083 | MOPC-21 | InVivoMab mouse IgG1 isotype control, unknown specificity |
| 11 | BE0273 | 29F.1A12 | InVivoMab anti-mouse PD-1 (CD279) |
| 12 | BE0164 | 9D9 | InVivoMab anti-mouse CTLA-4 (CD152) |
| 13 | BE0061 | 2.43 | InVivoMab anti-mouse CD8α |
| 14 | BE0088 | HRPN | InVivoMab rat IgG1 isotype control, anti-horseradish peroxidase |
| 15 | BP0083 | MOPC-21 | InVivoPlus mouse IgG1 isotype control, unknown specificity |
| 16 | BE0213 | AFS98 | InVivoMab anti-mouse CSF1R (CD115) |
| 17 | BE0036 | PK136 | InVivoMab anti-mouse NK1.1 |
| 18 | BP0164 | 9D9 | InVivoPlus anti-mouse CTLA-4 (CD152) |
| 19 | BE0085 | C1.18.4 | InVivoMab mouse IgG2a isotype control, unknown specificity |
| 20 | BP0090 | LTF-2 | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin |
InVivoMabとInVivoPlusの違いについて
| InVivoMab | InVivoPlus | |
| 純度 | >95% | >95% |
| タンパクの完全性 | SDS-PAGE検証済み | SDS-PAGE検証済み |
| エンドトキシン | <1EU/mg | <0.5EU/mg |
| WB/FC/ELISAによる検証 | 未検証 | 検証済み |
| タンパク凝集物≤5% | 未検証 | 検証済み |
| マウス病原体スクリーニング | 未検証 | 検証済み |
| 保存料およびキャリアタンパク質 | 不使用 | 不使用 |
| バルク容量対応 | 対応可能 | 対応可能 |
| in vivo試験での使用 | 使用可能 | 使用可能 |
| カタログ番号 | BEから | BPから |
商品リスト
-
in vivo用途向けに設計された抗体製品
-
InVivoMabより厳しいQCを受けた高品質抗体
-
アイソタイプコントロール
-
In vivoで利用できるタグ検出用の抗体
-
In vivo用途向きの厳密な検査を通過した緩衝液
-
抗体医薬品研究用のバイオシミラー
-
マウスやヒト化マウスでの免疫原性を抑えられるリコンビナント抗体
InVivoMab
研究分野
ターゲット
| BE0001-2FAB | InVivoMAb anti-human CD3 F(ab) fragment | 1/5/25 mg | |||||
| Clone | OKT-3 f(ab) Fragments | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0002FAB | InVivoMAb anti-mouse CD3 F(ab) fragment | 1/5/25 mg | |||||
| Clone | 17A2 f(ab) Fragments | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0004-1FAB | InVivoMAb anti-mouse CD8α F(ab) fragment | 1/5/25 mg | |||||
| Clone | 53-6.7 f(ab) Fragments | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BE0004-2FAB | InVivoMAb anti-human CD8α F(ab) fragment | 1/5/25 mg | |||||
| Clone | OKT-8 f(ab) Fragments | Isotype | Mouse IgG2a | ||||
| Recommended | Dilution Buffer: IPT060 | ||||||
| BE0061FAB | InVivoMAb anti-mouse CD8α F(ab) fragment | 1/5/25 mg | |||||
| Clone | 2.43 f(ab) Fragments | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0131FAB | InVivoMAb anti-mouse CTLA-4 (CD152) F(ab) fragment | 1/5/25 mg | |||||
| Clone | 9H10 f(ab) Fragment | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0174FAB | InVivoMAb anti-mouse LAG-3 F(ab) fragment | 1/5/25 mg | |||||
| Clone | C9B7W f(ab) Fragments | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0231FAB | InVivoMAb anti-human CD3 F(ab) fragment | 1/5/25 mg | |||||
| Clone | UCHT1 (Leu-4) (T3) f(ab) Fragments | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0280FAB | InVivoMAb anti-mouse c-Kit (CD117) f(ab')2 fragments | 1/5/25 mg | |||||
| Clone | 2B8 f(ab')2 Fragments | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0451 | InVivoMAb anti-mouse MHC Class I (H-2Db) | 1/5/25/50/100 mg | |||||
| Clone | 28-14-8S | Isotype | Mouse IgG2a, κ | ||||
| Application | MHC-I Immunopeptidomics, in vitro blocking of MHC-I , Immunocapture of peptide-MHC class - I complexes, Immunoprecipitation, Flow cytometry, Immunohistochemistry (frozen), ELISA | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0452 | InVivoMAb anti-human pan MHC Class II (HLA II) | 1/5/25/50/100 mg | |||||
| Clone | IVA12 | Isotype | Mouse IgG1, κ | ||||
| Application | in vitro blocking of MHC-II, MHC-II immunopeptidomics, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Immunohistochemistry (free floating), Flow cytometry, Immunofluorescence, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0453 | InVivoMAb anti-rat CD25 (IL-2Rα) | 1/5/25/50/100 mg | |||||
| Clone | OX-39 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0454 | InVivoMAb anti-human/mouse amphiregulin (AREG) | 1/5/25/50/100 mg | |||||
| Clone | AR37 | Isotype | Mouse IgG1, λ | ||||
| Application | in vivo blocking of amphiregulin (AREG), in vitro blocking of amphiregulin (AREG), Immunofluorescence, Western blot, ELISA | ||||||
| Recommended | Isotype Control: BE0093 Dilution Buffer: IP0070 | ||||||
| BE0455 | InVivoMAb anti-mouse CXCR4 (CD184) | 1/5/25/50/100 mg | |||||
| Clone | Cx4Mab-1 | Isotype | Rat IgG2a, κ | ||||
| Application | Flow cytometry, For details on in vivo applications please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0456 | InVivoMAb anti-mouse CXCR2 (CD182) | 1/5/25/50/100 mg | |||||
| Clone | Cx2Mab-1 | Isotype | Rat IgG2b, κ | ||||
| Application | Flow cytometry, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0457 | InVivoMAb anti-mouse CCR2 (CD192) | 1/5/25/50/100 mg | |||||
| Clone | C2Mab-6 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo CCR2 blockade*, Flow cytometry, ELISA, , * Refer to this JEM article for details - DOI: 10.1084/jem.20251114 | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0458 | InVivoMAb anti-human CD133 | 1/5/25/50/100 mg | |||||
| Clone | CMab-43 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo targeting of CD133, Flow cytometry, Immunohistochemistry (paraffin), Western blot, For details on in vivo applications please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0459 | InVivoMAb anti-human/monkey CD64 (FCGR1A) | 1/5/25/50/100 mg | |||||
| Clone | 10.1 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of FcγRI (CD64), in vitro blocking of FcγRI (CD64), in vivo imaging, Immunoprecipitation, Flow cytometry, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0460 | InVivoMAb anti-mouse BAFF-R (CD268) | 1/5/25/50/100 mg | |||||
| Clone | 9B9 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo blocking of BAFF-R, in vitro blocking of BAFF-R, Flow cytometry, , | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0461 | InVivoMAb anti-mouse/human/canine HER2 (domain III) (CD340) | 1/5/25/50/100 mg | |||||
| Clone | H2Mab-19 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo antitumor activity in HER2+ models, in vitro induction of ADCC in HER2+ cells, in vitro induction of CDC in HER2+ cells, Immunohistochemistry (frozen), Flow cytometry, | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0462 | InVivoMAb anti-mouse HER2 (domain I) (CD340) | 1/5/25/50/100 mg | |||||
| Clone | H2Mab-304 | Isotype | Rat IgG1, κ | ||||
| Application | Flow cytometry, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0463 | InVivoMAb anti-mouse CXCR6 (CD186) | 1/5/25/50/100 mg | |||||
| Clone | Cx6Mab-1 | Isotype | Rat IgG1, κ | ||||
| Application | Flow cytometry, Western blotting, ELISA, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0464 | InVivoMAb anti-mouse CCR8 (CDw198) | 1/5/25/50/100 mg | |||||
| Clone | C8Mab-2 | Isotype | Rat IgG2b, κ | ||||
| Application | Flow cytometry, Western blotting, Immunofluorescence, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0465 | InVivoMAb anti-mouse EGFR (domain I) | 1/5/25/50/100 mg | |||||
| Clone | EMab-300 | Isotype | Rat IgG1, κ | ||||
| Application | Flow cytometry, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0088 Dilution Buffer: IP0070 | ||||||
| BE0466 | InVivoMAb anti-mouse/human EGFR (domain III) | 1/5/25/50/100 mg | |||||
| Clone | EMab-88 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo EGFR blockade* , Flow cytometry, Western blot, , *Application reference: DOI 10.1021/acsnanomed.6c00046 | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0467 | InVivoMAb anti-mouse ACKR4 (CCR11) | 1/5/25/50/100 mg | |||||
| Clone | A4Mab-3 | Isotype | Rat IgG2b, κ | ||||
| Application | Flow cytometry, ELISA, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0468 | InVivoMAb anti-mouse MHC Class I (H-2Kb/H-2Db) | 1/5/25/50/100 mg | |||||
| Clone | 28-8-6S | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, Complement-dependent cytotoxicity (CDC), Immunohistochemistry (frozen), Flow cytometry, Immunopeptidomics, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0469 | InVivoMAb anti-human HLA-A2 | 1/5/25/50/100 mg | |||||
| Clone | BB7.2 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vitro functional assay, Immunopeptidomics, Immunoprecipitation, Flow cytometry, Immunofluorescence | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0470 | InVivoMAb anti-mouse CCR5 (CD195) | 1/5/25/50/100 mg | |||||
| Clone | C5Mab-2 | Isotype | Rat IgG2b, κ | ||||
| Application | Flow cytometry, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0471 | InVivoMAb anti-mouse NKp46 (CD335) | 1/5/25/50/100 mg | |||||
| Clone | 29A1.4 | Isotype | Rat IgG2a, κ | ||||
| Application | in vitro NK cell stimulation, Flow cytometry, Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0472 | InVivoMAb anti-human/monkey CXCR4 (CD184) | 1/5/25/50/100 mg | |||||
| Clone | 12G5 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of CXCR4, in vitro blocking of CXCR4, in vivo imaging, in vitro functional assay, Immunoprecipitation , flow cytometry , immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0473 | InVivoMAb anti-rat CD11b/c (OX42) | 1/5/25/50/100 mg | |||||
| Clone | OX-42 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of C3bi binding to CR3, in vitro blocking of C3bi binding to CR3, in vitro functional assay, Immunoprecipitation, Flow cytometry, Immunofluorescence, Immunohistochemistry (paraffin) , Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0474 | InVivoMAb anti-rat pan-CD45 (OX1) | 1/5/25/50/100 mg | |||||
| Clone | OX-1 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo functional assay, in vitro functional assay, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Flow cytometry, Immunofluorescence, Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0475 | InVivoMAb anti-rat CD45RC (OX22) | 1/5/25/50/100 mg | |||||
| Clone | OX-22 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo depletion of CD45RChigh cells, ex vivo depletion of CD45RChigh cells, in vitro selection of CD45RC+ cells, in vitro functional assay, Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Immunofluorescence, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0476 | InVivoMAb anti-rat L-selectin (CD62L) | 1/5/25/50/100 mg | |||||
| Clone | OX-85 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of L-selectin (CD62L), in vitro blocking of L-selectin (CD62L), in vitro functional assay, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0477 | InVivoMAb anti-mouse/human CXCL12 (SDF-1) | 1/5/25/50/100 mg | |||||
| Clone | K15C | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo neutralization of CXCL12/SDF-1, in vitro neutralization of CXCL12/SDF-1, in vitro functional assay , Immunohistochemistry (frozen), Immunohistochemistry (paraffin), Immunoelectron microscopy, Immunofluorescence, Flow cytometry , ELISA, Western blot, Dot blot | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0478 | InVivoMAb anti-mouse C5aR (CD88) | 1/5/25/50/100 mg | |||||
| Clone | 20/70 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo blocking of C5aR, in vitro blocking of C5aR, in vitro functional assay, Flow cytometry, immunofluorescence | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0479 | InVivoMAb anti-mouse CD39 (Entpd1) | 1/5/25/50/100 mg | |||||
| Clone | C39Mab-1 | Isotype | Rat IgG2a, κ | ||||
| Application | Flow cytometry, Western blot, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0480 | InVivoMAb anti-human CD6 (T12) | 1/5/25/50/100 mg | |||||
| Clone | UMCD6 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo functional assay , in vitro functional assay, in vitro activation of cytotoxic lymphocytes, Immunoprecipitation, Flow cytometry, Immunofluorescence, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0481 | InVivoMAb anti-mouse/human CD6 | 1/5/25/50/100 mg | |||||
| Clone | 6C1 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vitro functional blockade of CD6, in vivo functional blockade of CD6, in vitro functional assay , Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0482 | InVivoMAb anti-human/rat/mouse CD36 (FAT) | 1/5/25/50/100 mg | |||||
| Clone | FA6-152 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blockade of CD36, in vitro blockade of CD36, Immunoprecipitation, Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0483 | InVivoMAb anti-human HLA-E | 1/5/25/50/100 mg | |||||
| Clone | 3D12 | Isotype | Mouse IgG1, κ | ||||
| Application | Immunopeptidomics, immunoprecipitation, in vitro blocking of HLA-E, in vitro functional assay, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Immunofluorescence, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0485 | InVivoMAb anti-mouse CXCR5 (CD185) | 1/5/25/50/100 mg | |||||
| Clone | Cx5Mab-3 | Isotype | Rat IgG2b, κ | ||||
| Application | Flow cytometry, ELISA, For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BE0486 | InVivoMAb anti-mouse CCR7 (CD197) | 1/5/25/50/100 mg | |||||
| Clone | C7Mab-2 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CCR7 blockade*, Flow cytometry, ELISA, Immunohistochemistry (paraffin), *Refer to this Cell Host & Microbe article for details - DOI: 10.1016/j.chom.2026.06.021 | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0487 | InVivoMAb anti-mouse CD30L (CD153) | 1/5/25/50/100 mg | |||||
| Clone | RM153 | Isotype | Rat IgG2b | ||||
| Application | Flow cytometry, in vivo blocking, Functional assays, in vivo depletion of CD30L + T cells | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0488 | InVivoMAb anti-mouse IFN-α | 1/5/25/50/100 mg | |||||
| Clone | TIF-3C5 | Isotype | Armenian Hamster IgG1 | ||||
| Application | in vivo neutralization of IFN-α, in vitro neutralization of IFN-α, ELISA | ||||||
| Recommended | Isotype Control: BE0260 Dilution Buffer: IP0070 | ||||||
| BE0489 | InVivoMAb anti-mouse IFN-β | 1/5/25/50/100 mg | |||||
| Clone | HDβ-4A7 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo neutralization of IFN-β, in vitro neutralization of IFN-β, ELISA | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| BE0490 | InVivoMAb anti-mouse TNFR1 (CD120a) | 1/5/25/50/100 mg | |||||
| Clone | 55R-170 | Isotype | Armenian Hamster IgG1 | ||||
| Application | in vivo TNFR1 blockade, in vitro TNFR1 blockade , Immunoprecipitation, Western blot | ||||||
| Recommended | Isotype Control: BE0260 Dilution Buffer: IP0070 | ||||||
| BE0491 | InVivoMAb anti-mouse TNFR1 (CD120a) | 1/5/25/50/100 mg | |||||
| Clone | 55R-593 | Isotype | Armenian Hamster IgG1 | ||||
| Application | in vivo TNFR1 stimulation, in vitro TNFR1 stimulation, Immunoprecipitation, Western blot | ||||||
| Recommended | Isotype Control: BE0260 Dilution Buffer: IP0070 | ||||||
| BE0492 | InVivoMAb anti-mouse CD155 (PVR) | 1/5/25/50/100 mg | |||||
| Clone | 4.24 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo neutralization of CD155, in vitro neutralization of CD155, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0493 | InVivoMAb anti-mouse CD226 (DNAM-1) | 1/5/25/50/100 mg | |||||
| Clone | 480.1 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blockade of CD226, in vitro blockade of CD226, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0494FAB | InVivoMAb anti-human CD3 F(ab) fragment | 1/5/25 mg | |||||
| Clone | UCHT2 f(ab) Fragments | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0494 | InVivoMAb anti-human/monkey CD5 | 1/5/25/50/100 mg | |||||
| Clone | UCHT2 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CAR-T generation via antibody-conjugated tLNP mRNA delivery, in vitro functional assay, Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry, Immunoprecipitation, Western blot | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IPT060 | ||||||
| BE0495 | InVivoMAb anti-Chikungunya E2 Protein (CHIKV E2) | 1/5/25/50/100 mg | |||||
| Clone | CHK-152 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo neutralization of CHIKV E2, in vitro neutralization of CHIKV E2, Antibody-dependent cellular phagocytosis (ADCP), Antibody-dependent neutrophil phagocytosis (ADNP), Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0496 | InVivoMAb anti-Chikungunya E1 Protein (CHIKV E1) | 1/5/25/50/100 mg | |||||
| Clone | CHK-166 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo neutralization of CHIKV E1, in vitro neutralization of CHIKV E1, Antibody-dependent cellular phagocytosis (ADCP), Antibody-dependent neutrophil phagocytosis (ADNP), Immunohistochemistry (frozen), Immunofluorescence, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: BE0366 Dilution Buffer: IP0070 | ||||||
| BE0498 | InVivoMAb anti-mouse CD38 | 1/5/25/50/100 mg | |||||
| Clone | Ab90 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD38 stimulation , in vitro CD38 stimulation, Flow cytometry, Immunofluorescence, Immunohistochemistry (frozen), Antibody-drug conjugate synthesis, Functional assays, Immunoprecipitation, ELISA | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0500 | InVivoMAb anti-mouse CD28 | 1/5/25/50/100 mg | |||||
| Clone | E18 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo blocking of CD28-B7 signaling, in vitro blocking of CD28-B7 signaling, in vitro T cell co-stimulation with anti-CD3, in vitro Organoids/Organ-on-Chip, in vitro functional assay, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0086 Dilution Buffer: IP0070 | ||||||
| BE0501 | InVivoMAb anti-mouse CD2 | 1/5/25/50/100 mg | |||||
| Clone | RM2-5 | Isotype | Rat IgG2b, λ | ||||
| Application | in vivo CD2 blockade, in vitro CD2 blockade, in vivo antibody-mediated cell targeting for therapeutic nanoparticle delivery, ex vivo depletion - magnetic bead based negative selection, Functional Assay, Flow cytometry, Immunoprecipitation, , | ||||||
| Recommended | Isotype Control: BE0090 Dilution Buffer: IP0070 | ||||||
| BE0502 | InVivoMAb anti-human MHC class II (HLA-DP) | 1/5/25/50/100 mg | |||||
| Clone | B7/21 | Isotype | Mouse IgG3, κ | ||||
| Application | Immunopeptidomics, Immunoprecipitation , in vitro blocking of HLA-DP , in vitro functional assays, Flow cytometry, Immunohistochemistry (frozen), ELISA | ||||||
| Recommended | Isotype Control: BE0093 Dilution Buffer: IP0070 | ||||||
| BE0506 | InVivoMAb anti-human CD7 | 1/5/25/50/100 mg | |||||
| Clone | 124-1D1 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo functional assay, in vitro functional assay, in vitro CD7+ T cell capture, flow cytometry | ||||||
| Recommended | Isotype Control: BE0083 Dilution Buffer: IP0070 | ||||||
| BE0507FAB2 | InVivoMAb anti-mouse CD5 f(ab')2 fragments | 1/5/25 mg | |||||
| Clone | 53-7.3 f(ab')2 Fragments | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0507 | InVivoMAb anti-mouse CD5 | 1/5/25/50/100 mg | |||||
| Clone | 53-7.3 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of CD5, in vitro blocking of CD5 , Functional assays, Flow cytometry, Immunofluorescence, Immunohistochemistry (frozen), Immunoprecipitation | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
| BE0510 | InVivoMAb anti-mouse IL-33R (ST2) | 1/5/25/50/100 mg | |||||
| Clone | BXC-06E01 | Isotype | Rat IgG2a, κ | ||||
| Application | in vitro neutralization of mouse IL-33R (ST2), Functional assays , ELISA , Western blot, , For details on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: BE0089 Dilution Buffer: IP0070 | ||||||
InVivoPlus
研究分野
ターゲット
| BP0001-1 | InVivoPlus anti-mouse CD3ε | 5/25/50/100 mg | |||||
| Clone | 145-2C11 | Isotype | Armenian Hamster IgG1 | ||||
| Application | in vivo T cell depletion, in vitro T cell stimulation/activation, Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0070 | ||||||
| BP0003-1 | InVivoPlus anti-mouse CD4 | 5/25/50/100 mg | |||||
| Clone | GK1.5 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD4+ T cell depletion, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0065 | ||||||
| BP0003-3 | InVivoPlus anti-mouse CD4 | 5/25/50/100 mg | |||||
| Clone | YTS 177 | Isotype | Rat IgG2a | ||||
| Application | in vivo blockade of CD4+ T-cell responses, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0004-1 | InVivoPlus anti-mouse CD8α | 5/25/50/100 mg | |||||
| Clone | 53-6.7 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo CD8+ T cell depletion, Immunofluorescence, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0065 | ||||||
| BP0012 | InVivoPlus anti-mouse CD25 (IL-2Rα) | 5/25/50/100 mg | |||||
| Clone | PC-61.5.3 | Isotype | Rat IgG1, λ | ||||
| Application | in vivo regulatory T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0016-2 | InVivoPlus anti-mouse CD40 | 5/25/50/100 mg | |||||
| Clone | FGK4.5/FGK45 | Isotype | Rat IgG2a | ||||
| Application | in vivo CD40 activation, in vitro B cell stimulation/activation | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0017-1 | InVivoPlus anti-mouse CD40L (CD154) | 5/25/50/100 mg | |||||
| Clone | MR-1 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of CD40/CD40L signaling, in vitro blocking of CD40/CD40L signaling, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0070 | ||||||
| BP0031 | InVivoPlus anti-mouse OX40 (CD134) | 5/25/50/100 mg | |||||
| Clone | OX-86 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo OX40 activation, in vitro OX40 activation, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0032 | InVivoPlus anti-mouse CTLA-4 (CD152) | 5/25/50/100 mg | |||||
| Clone | UC10-4F10-11 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0065 | ||||||
| BP0033-2 | InVivoPlus anti-mouse PD-1 (CD279) | 5/25/50/100 mg | |||||
| Clone | J43 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0065 | ||||||
| BP0036 | InVivoPlus anti-mouse NK1.1 | 5/25/50/100 mg | |||||
| Clone | PK136 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo NK cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| BP0045 | InVivoPlus anti-mouse IL-4 | 5/25/50/100 mg | |||||
| Clone | 11B11 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IL-4 neutralization, in vitro IL-4 neutralization, in vivo IL-4 receptor stimulation (as a complex with IL-4), Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0050 | InVivoPlus anti-mouse IL-10R (CD210) | 5/25/50/100 mg | |||||
| Clone | 1B1.3A | Isotype | Rat IgG1, κ | ||||
| Application | in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, Flow cytometry, Western Blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IPT065 | ||||||
| BP0051 | InVivoPlus anti-mouse IL-12 p40 | 5/25/50/100 mg | |||||
| Clone | C17.8 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo IL-12p40 neutralization, p40 affinity chromatography, Immunoprecipitation, ELISA, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0055 | InVivoPlus anti-mouse IFNγ | 5/25/50/100 mg | |||||
| Clone | XMG1.2 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo IFNγ neutralization, in vitro IFNγ neutralization, ELISPOT, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IPT080 | ||||||
| BP0057 | InVivoPlus anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-β | 5/25/50/100 mg | |||||
| Clone | 1D11.16.8 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo TGFβ neutralization, in vitro TGFβ neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0058 | InVivoPlus anti-mouse TNFα | 5/25/50/100 mg | |||||
| Clone | XT3.11 | Isotype | Rat IgG1 | ||||
| Application | in vivo TNFα neutralization, in vitro TNFα neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0080 | ||||||
| BP0060 | InVivoPlus anti-mouse VEGFR-2 | 5/25/50/100 mg | |||||
| Clone | DC101 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0061 | InVivoPlus anti-mouse CD8α | 5/25/50/100 mg | |||||
| Clone | 2.43 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0063 | InVivoPlus anti-mouse GITR | 5/25/50/100 mg | |||||
| Clone | DTA-1 | Isotype | Rat IgG2b, λ | ||||
| Application | in vivo GITR stimulation | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0066 | InVivoPlus anti-mouse Thy1.2 (CD90.2) | 5/25/50/100 mg | |||||
| Clone | 30H12 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo ILC depletion, in vivo T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0075-1 | InVivoPlus anti-mouse Ly6G | 5/25/50/100 mg | |||||
| Clone | 1A8 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo neutrophil depletion, in vivo MDSC depletion, Immunofluorescence, Immunohistochemistry (paraffin), Immunohistochemistry (frozen), Flow cytometry | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0075 | InVivoPlus anti-mouse Ly6G/Ly6C (Gr-1) | 5/25/50/100 mg | |||||
| Clone | RB6-8C5 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo depletion of Gr-1+ myeloid cells, Flow cytometry, Immunohistochemistry (paraffin), Immunohistochemistry (frozen) | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0079 | InVivoPlus anti-human MHC Class I (HLA-A, HLA-B, HLA-C) | 5/25/50/100 mg | |||||
| Clone | W6/32 | Isotype | Mouse IgG2a, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0065 | ||||||
| BP0083 | InVivoPlus mouse IgG1 isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MOPC-21 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0085 | InVivoPlus mouse IgG2a isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | C1.18.4 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0086 | InVivoPlus mouse IgG2b isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MPC-11 | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0087 | InVivoPlus polyclonal Syrian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Syrian hamster IgG | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0088 | InVivoPlus rat IgG1 isotype control, anti-horseradish peroxidase | 5/25/50/100 mg | |||||
| Clone | HRPN-CP167 | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0089 | InVivoPlus rat IgG2a isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | 2A3 | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0090 | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin | 5/25/50/100 mg | |||||
| Clone | LTF-2-CP166 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0091 | InVivoPlus polyclonal Armenian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Armenian hamster IgG | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0096 | InVivoPlus recombinant human IgG1 Fc | 5/25/50/100 mg | |||||
| Clone | human Fc-G1 | Isotype | |||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0099 | InVivoPlus recombinant CTLA-4-Ig (hum/hum) | 5/25/50/100 mg | |||||
| Clone | CTLA-4-Ig (hum/hum) | Isotype | |||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0101 | InVivoPlus anti-mouse PD-L1 (B7-H1) | 5/25/50/100 mg | |||||
| Clone | 10F.9G2™ | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo PD-L1 blockade, in vitro PD-L1 blockade, Immunofluorescence, Immunohistochemistry (frozen), Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0065 | ||||||
| BP0115 | InVivoPlus anti-mouse TIM-3 (CD366) | 5/25/50/100 mg | |||||
| Clone | RMT3-23 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo TIM-3 neutralization, in vitro TIM-3 blocking, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0117 | InVivoPlus anti-mouse CD8α | 5/25/50/100 mg | |||||
| Clone | YTS 169.4 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0070 | ||||||
| BP0131 | InVivoPlus anti-mouse CTLA-4 (CD152) | 5/25/50/100 mg | |||||
| Clone | 9H10 | Isotype | Syrian Hamster IgG | ||||
| Application | in vivo CTLA-4 neutralization, in vitro CTLA-4 neutralization, Western blot | ||||||
| Recommended | Isotype Control: BP0087 Dilution Buffer: IP0070 | ||||||
| BP0146 | InVivoPlus anti-mouse PD-1 (CD279) | 5/25/50/100 mg | |||||
| Clone | RMP1-14 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0164 | InVivoPlus anti-mouse CTLA-4 (CD152) | 5/25/50/100 mg | |||||
| Clone | 9D9 | Isotype | Mouse IgG2b | ||||
| Application | in vivo CTLA-4 neutralization, Western blot, in vivo intra-tumoral regulatory T cell depletion | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0070 | ||||||
| BP0169 | InVivoPlus anti-mouse 4-1BB (CD137) | 5/25/50/100 mg | |||||
| Clone | LOB12.3 | Isotype | Rat IgG1, κ | ||||
| Application | in vivo activation of 4-1BB | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0080 | ||||||
| BP0173 | InVivoPlus anti-mouse/rat IL-17A | 5/25/50/100 mg | |||||
| Clone | 17F3 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IL-17A neutralization, ELISA | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0174 | InVivoPlus anti-mouse LAG-3 | 5/25/50/100 mg | |||||
| Clone | C9B7W | Isotype | Rat IgG1, κ | ||||
| Application | in vivo LAG-3 neutralization, in vitro LAG-3 neutralization, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0088 Dilution Buffer: IP0070 | ||||||
| BP0175 | InVivoPlus anti-mouse CD71 (TfR1) | 5/25/50/100 mg | |||||
| Clone | R17 217.1.3/TIB-219 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo depletion of CD71+ cells | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0213 | InVivoPlus anti-mouse CSF1R (CD115) | 5/25/50/100 mg | |||||
| Clone | AFS98 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo macrophage depletion, in vitro CSF1R neutralization, in vivo monocyte depletion, Flow cytometry, Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0239 | InVivoPlus anti-mouse 4-1BB (CD137) | 5/25/50/100 mg | |||||
| Clone | 3H3 | Isotype | Rat IgG2a | ||||
| Application | in vivo 4-1BB stimulation, in vitro 4-1BB stimulation | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0241 | InVivoPlus anti-mouse IFNAR-1 | 5/25/50/100 mg | |||||
| Clone | MAR1-5A3 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade, Western blot | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0273 | InVivoPlus anti-mouse PD-1 (CD279) | 5/25/50/100 mg | |||||
| Clone | 29F.1A12™ | Isotype | Rat IgG2a | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, Immunohistochemistry (frozen), Immunofluorescence, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0274 | InVivoPlus anti-mouse TIGIT | 5/25/50/100 mg | |||||
| Clone | 1G9 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo TIGIT stimulation, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0283 | InVivoPlus anti-mouse/human/rat CD47 (IAP) | 5/25/50/100 mg | |||||
| Clone | MIAP410 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CD47 blockade, in vitro CD47 blocking, Immunofluorescence | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| BP0290 | InVivoPlus rat IgG1 isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | TNP6A7 | Isotype | Rat IgG1, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0297 | InVivoPlus human IgG1 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG1 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0298 | InVivoPlus anti-mouse CD122 (IL-2Rβ) | 5/25/50/100 mg | |||||
| Clone | TM-Beta 1 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo NK cell depletion, in vivo CD122 blockade, in vitro IL-2R blockade, Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0080 | ||||||
| BP0301 | InVivoPlus human IgG2 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG2 | Isotype | Human IgG2, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0307 | InVivoPlus anti-mouse CD16/CD32 | 5/25/50/100 mg | |||||
| Clone | 2.4G2 | Isotype | Rat IgG2b, κ | ||||
| Application | in vivo Fc receptor blocking, Fc receptor blocking, flow cytometry, Fc receptor blocking, immunofluorescence | ||||||
| Recommended | Isotype Control: BP0090 Dilution Buffer: IP0080 | ||||||
| BP0308 | InVivoPlus anti-rat CD4 | 5/25/50/100 mg | |||||
| Clone | OX-38 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD4+ T cell depletion, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| BP0310 | InVivoPlus anti-mouse VISTA | 5/25/50/100 mg | |||||
| Clone | 13F3 | Isotype | Armenian Hamster IgG | ||||
| Application | in vivo blocking of VISTA signaling, in vitro blocking of VISTA signaling, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0091 Dilution Buffer: IP0070 | ||||||
| BP0329 | InVivoPlus anti-mouse CD71 (TfR1) | 5/25/50/100 mg | |||||
| Clone | 8D3 | Isotype | Rat IgG2a | ||||
| Application | in vivo depletion of CD71+ cells, Immunofluorescence, Immunohistochemistry (frozen), Western blot | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| BP0356 | InVivoPlus anti-mouse CD20 | 5/25/50/100 mg | |||||
| Clone | MB20-11 | Isotype | Mouse IgG2c, κ | ||||
| Application | in vivo B cell depletion, Western blot | ||||||
| Recommended | Isotype Control: BP0366 Dilution Buffer: IP0070 | ||||||
| BP0366 | InVivoPlus mouse IgG2c isotype control, anti-dengue virus | 5/25/50/100 mg | |||||
| Clone | DV5-1 | Isotype | Mouse IgG2c, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
Isotype Control
| BE0083 | InVivoMAb mouse IgG1 isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BE0085 | InVivoMAb mouse IgG2a isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | C1.18.4 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0086 | InVivoMAb mouse IgG2b isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MPC-11 | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0087 | InVivoMAb polyclonal Syrian hamster IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal Syrian hamster IgG | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0088 | InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase | 1/5/25/50/100 mg | |||||
| Clone | HRPN-CP167 | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0089 | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol | 1/5/25/50/100 mg | |||||
| Clone | 2A3 | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BE0090 | InVivoMAb rat IgG2b isotype control, anti-keyhole limpet hemocyanin | 1/5/25/50/100 mg | |||||
| Clone | LTF-2-CP166 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0091 | InVivoMAb polyclonal Armenian hamster IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal Armenian hamster IgG | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0092 | InVivoMAb polyclonal human IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal human IgG | Isotype | Human IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0093 | InVivoMAb polyclonal mouse IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal mouse IgG | Isotype | Mouse IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0094 | InVivoMAb polyclonal rat IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal rat IgG | Isotype | Rat IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0095 | InVivoMAb polyclonal rabbit IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal rabbit IgG | Isotype | Rabbit IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0130 | InVivoMAb polyclonal goat IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal goat IgG | Isotype | Goat IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0260 | InVivoMAb Armenian hamster IgG isotype control, anti-glutathione S-transferase | 1/5/25/50/100 mg | |||||
| Clone | PIP | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0297 | InVivoMAb human IgG1 isotype control | 1/5/25/50/100 mg | |||||
| Clone | human IgG1 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0301 | InVivoMAb human IgG2 isotype control | 1/5/25/50/100 mg | |||||
| Clone | human IgG2 | Isotype | Human IgG2, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0366 | InVivoMAb mouse IgG2c isotype control, anti-dengue virus | 1/5/25/50/100 mg | |||||
| Clone | DV5-1 | Isotype | Mouse IgG2c, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BE0369 | InVivoMAb polyclonal llama IgG | 1/5/25/50/100 mg | |||||
| Clone | polyclonal llama IgG | Isotype | Llama IgG | ||||
| Recommended | Dilution Buffer: - | ||||||
| BE0425 | InVivoMAb rat IgG2b isotype control, anti-trinitrophenol-keyhole limpet hemocyanin | 1/5/25/50/100 mg | |||||
| Clone | TNP-4G1 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0083 | InVivoPlus mouse IgG1 isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MOPC-21 | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0085 | InVivoPlus mouse IgG2a isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | C1.18.4 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0086 | InVivoPlus mouse IgG2b isotype control, unknown specificity | 5/25/50/100 mg | |||||
| Clone | MPC-11 | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0087 | InVivoPlus polyclonal Syrian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Syrian hamster IgG | Isotype | Syrian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0088 | InVivoPlus rat IgG1 isotype control, anti-horseradish peroxidase | 5/25/50/100 mg | |||||
| Clone | HRPN-CP167 | Isotype | Rat IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0089 | InVivoPlus rat IgG2a isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | 2A3 | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0065 | ||||||
| BP0090 | InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin | 5/25/50/100 mg | |||||
| Clone | LTF-2-CP166 | Isotype | Rat IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0091 | InVivoPlus polyclonal Armenian hamster IgG | 5/25/50/100 mg | |||||
| Clone | polyclonal Armenian hamster IgG | Isotype | Armenian Hamster IgG | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0290 | InVivoPlus rat IgG1 isotype control, anti-trinitrophenol | 5/25/50/100 mg | |||||
| Clone | TNP6A7 | Isotype | Rat IgG1, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0297 | InVivoPlus human IgG1 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG1 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0301 | InVivoPlus human IgG2 isotype control | 5/25/50/100 mg | |||||
| Clone | human IgG2 | Isotype | Human IgG2, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| BP0366 | InVivoPlus mouse IgG2c isotype control, anti-dengue virus | 5/25/50/100 mg | |||||
| Clone | DV5-1 | Isotype | Mouse IgG2c, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP047 | RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP048 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP049 | RecombiMAb mouse IgG2b (LALA-PG) isotype control, anti-hen egg lysozyme | 1 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP147 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP148 | RecombiMAb human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP149 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP150 | RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP152 | RecombiMAb human IgG4 (S228P) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP152 | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP156 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP156 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP160 | RecombiMAb mouse IgG2a isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP160 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP161 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP161 | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP169 | RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP169 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP171 | RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP173 | RecombiMAb human IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP174 | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP175 | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP179 | RecombiMAb HIS human IgG1 F(ab) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP180 | RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG2, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP181 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP183 | RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP186 | RecombiMAb Armenian hamster IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Armenian Hamster IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP188 | RecombiMAb rat IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP189 | RecombiMAb mouse IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP190 | RecombiMAb mouse IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP191 | RecombiMAb mouse IgG2b isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
Ready Tag
| RT0263 | ReadyTag anti-c-myc | 1/5/25 mg | |||||
| Clone | 9E10 | Isotype | Mouse IgG1 | ||||
| Application | Western blot, ELISA, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0264 | ReadyTag anti-GST | 1/5/25 mg | |||||
| Clone | F50-3D12.2 | Isotype | Mouse IgG1 | ||||
| Application | Western blot | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0265 | ReadyTag anti-GFP | 1/5/25 mg | |||||
| Clone | F56-6A1.2.3 | Isotype | Mouse IgG2b | ||||
| Application | Western blot, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0266 | ReadyTag anti-6-His | 1/5/25 mg | |||||
| Clone | 6-His | Isotype | Mouse IgG1 | ||||
| Application | Western blot, Immunoprecipitation, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0267 | ReadyTag anti-OVA | 1/5/25 mg | |||||
| Clone | F2-3.58 | Isotype | Mouse IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0268 | ReadyTag anti-HA | 1/5/25 mg | |||||
| Clone | 12CA5 | Isotype | Mouse IgG2b | ||||
| Application | ELISA, Western blot, Immunoprecipitation, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| RT0269 | ReadyTag anti-DDDDK | 1/5/25 mg | |||||
| Clone | AP1501 | Isotype | Mouse IgG2b | ||||
| Application | Western blot, Immunoprecipitation, Immunofluorescence | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
InVivoPure Dilution Buffer
| IP0065 | InVivoPure pH 6.5 Dilution Buffer | 50 ml | |||||
| IP0070 | InVivoPure pH 7.0 Dilution Buffer | 50 ml | |||||
| IP0080 | InVivoPure pH 8.0 Dilution Buffer | 50 ml | |||||
| IPT060 | InVivoPure pH 6.0T Dilution Buffer | 50 ml | |||||
| IPT065 | InVivoPure pH 6.5T Dilution Buffer | 50 ml | |||||
| IPT080 | InVivoPure pH 8.0T Dilution Buffer | 50 ml | |||||
InVivoSIM
| SIM0001 | InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Adalimumab | Isotype | Human IgG1 | ||||
| Application | in vitro TNFα neutralization, in vitro functional assay, Flow Cytometry, ELISA, Immunofluoresence, Immunoprecipitation, Immunohistochemistry, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0002 | InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Cetuximab | Isotype | Human IgG1 | ||||
| Application | in vitro EGFR2+ cell depletion (ADCC assay), in vitro functional assay, EGFR blockade, in vivo imaging, Immunohistochemistry (frozen), Immunofluorescence, Flow Cytometry, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0003 | InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Nivolumab | Isotype | Human IgG4 | ||||
| Application | in vitro PD-1 neutralization, in vivo blocking of PD-1/PD-L signaling, in vitro functional assay, in vivo functional assay, Flow Cytometry, Immunohistochemistry, Western Blot | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0004 | InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ipilimumab | Isotype | Human IgG1 | ||||
| Application | in vitro CTLA-4 neutralization, in vivo CTLA-4 neutralization, Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0005 | InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Trastuzumab | Isotype | Human IgG1 | ||||
| Application | in vitro HER2+ cell depletion (ADCC assay), Antibody-drug conjugate synthesis, in vitro functional assays, in vivo functional assays, Flow Cytometry, ELISA, Immunohistochemistry, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0006 | InVivoSIM anti-human TNFα (Infliximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Infliximab | Isotype | Human IgG1 | ||||
| Application | in vitro TNFα neutralization , in vitro functional assay, Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0007 | InVivoSIM anti-human VEGF (Bevacizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Bevacizumab | Isotype | Human IgG1 | ||||
| Application | VEGF neutralization, Flow Cytometry, ELISA, Immunoprecipitation, Western Block | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0008 | InVivoSIM anti-human CD20 (Rituximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Rituximab | Isotype | Human IgG1 | ||||
| Application | in vivo functional assay, in vitro functional assay, in vitro CD20+ cell depletion (ADCC assay), Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0009 | InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Atezolizumab | Isotype | Human IgG1 | ||||
| Application | in vivo PD-L1 blockade, Flow Cytometry, Western Blot | ||||||
| Recommended | Isotype Control: CP171 Dilution Buffer: IP0070 | ||||||
| SIM0010 | InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Pembrolizumab | Isotype | Human IgG4 | ||||
| Application | in vivo blocking of PD-1/PD-L signaling, in vitro blocking of PD-1/PD-L signaling, in vitro functional assay | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0011 | InVivoSIM anti-human C5 (Eculizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Eculizumab | Isotype | Human IgG4 | ||||
| Application | Inhibition of the activation of C5, Functional assays, ELISA, Immunoprecipitation | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0012 | InVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ramucirumab | Isotype | Human IgG1 | ||||
| Application | Functional assays, Immunohistochemistry, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0013 | InVivoSIM anti-human IL-17A (Secukinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Secukinumab | Isotype | Human IgG1 | ||||
| Application | in vitro IL-17A neutralization, Functional assays, Immunofluorescence, Immunohistochemistry, Flow Cytometry, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0014 | InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tocilizumab | Isotype | Human IgG1 | ||||
| Application | Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0015 | InVivoSIM anti-human LAG-3 (Relatlimab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Relatlimab | Isotype | Human IgG4, κ | ||||
| Application | ELISA | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0016 | InVivoSIM anti-human IgE (Omalizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Omalizumab | Isotype | Human IgG1, κ | ||||
| Application | IgE neutralization, Flow cytometry, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0017 | InVivoSIM anti-human NGF (Tanezumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tanezumab | Isotype | Human IgG2, κ | ||||
| Application | in vivo NGF neutralization, ELISA | ||||||
| Recommended | Isotype Control: BP0301 Dilution Buffer: IP0070 | ||||||
| SIM0018 | InVivoSIM anti-human integrin α4β1 (VLA-4) | 1/5/25/50/100 mg | |||||
| Clone | Natalizumab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays, Flow cytometry | ||||||
| Recommended | Isotype Control: BE0092 Dilution Buffer: IP0070 | ||||||
| SIM0019 | InVivoSIM anti-human HER2 (Pertuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Pertuzumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Neutralization | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0020 | InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ustekinumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0021 | InVivoSIM anti-human PD-L1 (Avelumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Avelumab | Isotype | Human IgG1, λ | ||||
| Application | in vitro functional assay, in vitro PD-L1 blockade, ELISA | ||||||
| Recommended | Isotype Control: CP169 Dilution Buffer: IP0070 | ||||||
| SIM0022 | InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Anifrolumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, Western blot, ELISA | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
| SIM0023 | InVivoSIM anti-human IL-4Rα (CD124) (Dupilumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Dupilumab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0024 | InVivoSIM anti-human integrin α4β7 (LPAM-1) (Vedolizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Vedolizumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP149 Dilution Buffer: IP0070 | ||||||
| SIM0025 | InVivoSIM anti-human IL-23 (p19) (Guselkumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Guselkumab | Isotype | Human IgG1, λ | ||||
| Application | IL-23p19 neutralization, Functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP169 Dilution Buffer: IP0070 | ||||||
| SIM0026 | InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Zolbetuximab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0027 | InVivoSIM anti-human PD-L1 (Durvalumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Durvalumab | Isotype | Human IgG1, κ | ||||
| Application | ELISA, Flow Cytometry, Western Blot, Functional assays | ||||||
| Recommended | Isotype Control: CP149 Dilution Buffer: IP0070 | ||||||
| SIM0028 | InVivoSIM anti-human RANKL (CD254) (Denosumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Denosumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, Flow Cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0029 | InVivoSIM anti-human IL-17A (Ixekizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Ixekizumab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays, ELISA, Immunofluorescence, Flow Cytometry, Western blot | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0030 | InVivoSIM anti-human IL-6 (Siltuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Siltuximab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0031 | InVivoSIM anti-human nectin-4 (Enfortumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Enfortumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0032 | InVivoSIM anti-human amyloid-beta (Lecanemab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Lecanemab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0033 | InVivoSIM anti-human TIGIT (Tiragolumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tiragolumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0297 Dilution Buffer: IP0070 | ||||||
| SIM0034 | InVivoSIM anti-human CD38 (Daratumumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Daratumumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
| SIM0035 | InVivoSIM anti-human CD25 (IL-2Rα) (Daclizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Daclizumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP173 Dilution Buffer: IP0070 | ||||||
| SIM0036 | InVivoSIM anti-human TSLP (Tezepelumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tezepelumab | Isotype | Human IgG2, λ | ||||
| Application | Functional assays | ||||||
| Recommended | Isotype Control: BP0301 Dilution Buffer: IP0070 | ||||||
| SIM0037 | InVivoSIM anti-human PD-1 (Cemiplimab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Cemiplimab | Isotype | Human IgG4, κ | ||||
| Application | Blocking of PD-1/PD-L signaling, Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0038 | InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tislelizumab | Isotype | Human IgG4, κ | ||||
| Application | Blocking of PD-1/PD-L signaling, Functional assays, ELISA | ||||||
| Recommended | Isotype Control: CP183 Dilution Buffer: IP0070 | ||||||
| SIM0039 | InVivoSIM anti-human CEACAM5 (Labetuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Labetuzumab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0040 | InVivoSIM anti-human mesothelin (Amatuximab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Amatuximab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0041 | InVivoSIM anti-human SLAMF7 (Elotuzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Elotuzumab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Immunoprecipitation, Flow cytometry | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0042 | InVivoSIM anti-human IL-13 (Tralokinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tralokinumab | Isotype | Human IgG4, λ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: CP181 Dilution Buffer: IP0070 | ||||||
| SIM0043 | InVivoSIM anti-human TIM-3 (Sabatolimab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Sabatolimab | Isotype | Human IgG4, κ | ||||
| Application | Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: CP147 Dilution Buffer: IP0070 | ||||||
| SIM0044 | InVivoSIM anti-human IL-1β (Canakinumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Canakinumab | Isotype | Human IgG1, κ | ||||
| Application | Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
| SIM0045 | InVivoSIM anti-human CD326 (EpCAM) (Edrecolomab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Edrecolomab | Isotype | Mouse IgG2a, κ | ||||
| Application | Functional assays, ELISA, Flow cytometry | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| SIM0046 | InVivoSIM anti-human CTLA-4 (Tremelimumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Tremelimumab | Isotype | Human IgG2, κ | ||||
| Application | CTLA-4 neutralization, Flow Cytometry, ELISA, Western Blot | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| SIM0047 | InVivoSIM anti-human amyloid-beta (Solanezumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Solanezumab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot, Immunohistochemistry (paraffin) | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0048 | InVivoSIM anti-human amyloid beta (Donanemab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Donanemab | Isotype | Human IgG1, κ | ||||
| Application | in vivo functional assays, in vitro functional assays, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP174 Dilution Buffer: IP0070 | ||||||
| SIM0049 | InVivoSIM anti-human IL-1β (Gevokizumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Gevokizumab | Isotype | Human IgG2, κ | ||||
| Application | in vivo neutralization of human IL1β, in vitro neutralization of human IL1β, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP180 Dilution Buffer: IP0070 | ||||||
| SIM0050 | InVivoSIM anti-human EGFR (Panitumumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Panitumumab | Isotype | Human IgG2, κ | ||||
| Application | in vivo neutralization of human EGFR, in vitro neutralization of human EGFR, ELISA, Western blot | ||||||
| Recommended | Isotype Control: CP180 Dilution Buffer: IP0070 | ||||||
| SIM0051 | InVivoSIM anti-human TROP-2 (Sacituzumab Biosimilar) | 1/5/25/50/100 mg | |||||
| Clone | Sacituzumab | Isotype | Human IgG1, κ | ||||
| Application | in vitro functional assays, in vivo functional assays, Antibody-drug conjugate synthesis, ELISA, Western blot, Flow cytometry | ||||||
| Recommended | Isotype Control: CP175 Dilution Buffer: IP0070 | ||||||
RecombiMAb
| CP001 | RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) | 1 mg | |||||
| Clone | 10F.9G2™-CP001 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2b 10F.9G2 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP002 | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | 1 mg | |||||
| Clone | RMP1-14-CP002 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP005 | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | 1 mg | |||||
| Clone | 29F.1A12™-CP005 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP006 | RecombiMAb anti-mouse CTLA-4 (CD152) | 1 mg | |||||
| Clone | 9D9-CP006 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CTLA-4 neutralization*, Western blot* *Reported for the original mouse IgG2b 9D9 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP007 | RecombiMAb anti-mouse CTLA-4 (CD152) | 1 mg | |||||
| Clone | 9D9-CP007 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CTLA-4 neutralization*, Western blot* *Reported for the original mouse IgG2b 9D9 antibody | ||||||
| Recommended | Isotype Control: BE0085 Dilution Buffer: IP0070 | ||||||
| CP008 | RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG) | 1 mg | |||||
| Clone | 9D9-CP008 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CTLA-4 neutralization*, Western blot* *Reported for the original mouse IgG2b 9D9 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP013 | RecombiMAb anti-mouse LAG-3 (D265A) | 1 mg | |||||
| Clone | C9B7W-CP013 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot* *Reported for the original rat IgG1 C9B7W antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP014 | RecombiMAb anti-mouse LAG-3 | 1 mg | |||||
| Clone | C9B7W-CP014 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo LAG-3 neutralization*, in vitro LAG-3 neutralization*, Flow cytometry*, Western blot* *Reported for the original rat IgG1 C9B7W antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP017 | RecombiMAb anti-mouse OX40 (CD134) | 1 mg | |||||
| Clone | OX86-CP017 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo OX40 activation*, in vitro OX40 activation*, Western blot* *Reported for the original rat IgG1 OX-86 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP018 | RecombiMAb anti-mouse OX40 (CD134) (LALA-PG) | 1 mg | |||||
| Clone | OX86-CP018 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo OX40 activation*, in vitro OX40 activation*, Western blot* *Reported for the original rat IgG1 OX-86 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP025 | RecombiMAb anti-mouse CD16/CD32 | 1 mg | |||||
| Clone | 2.4G2-CP025 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo Fc receptor blocking*, Fc receptor blocking, flow cytometry*, Fc receptor blocking, immunofluorescence* *Reported for the original rat IgG2b 2.4G2 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP026 | RecombiMAb anti-mouse CD16/CD32 (LALA-PG) | 1 mg | |||||
| Clone | 2.4G2-CP026 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo Fc receptor blocking*, Fc receptor blocking, flow cytometry*, Fc receptor blocking, immunofluorescence* *Reported for the original rat IgG2b 2.4G2 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP027 | RecombiMAb anti-mouse GITR (D265A) | 1 mg | |||||
| Clone | DTA-1-CP027 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP028 | RecombiMAb anti-mouse GITR | 1 mg | |||||
| Clone | DTA-1-CP028 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP029 | RecombiMAb anti-mouse GITR (LALA-PG) | 1 mg | |||||
| Clone | DTA-1-CP029 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP031 | RecombiMAb anti-mouse GITR (LALA-PG) | 1 mg | |||||
| Clone | DTA-1-CP031 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo GITR stimulation* *Reported for the original rat IgG2b DTA-1 antibody | ||||||
| Recommended | Isotype Control: CP049 Dilution Buffer: IP0070 | ||||||
| CP032 | RecombiMAb anti-mouse CD40L (CD154) (D265A) | 1 mg | |||||
| Clone | MR-1-CP032 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot* *Reported for the original Armenian hamster IgG MR-1 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP033 | RecombiMAb anti-mouse CD40L (CD154) | 1 mg | |||||
| Clone | MR-1-CP033 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot* *Reported for the original Armenian hamster IgG MR-1 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP034 | RecombiMAb anti-mouse CD40L (CD154) (LALA-PG) | 1 mg | |||||
| Clone | MR-1-CP034 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of CD40/CD40L signaling*, in vitro blocking of CD40/CD40L signaling*, Western blot* *Reported for the original Armenian hamster IgG MR-1 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP038 | RecombiMAb anti-mouse 4-1BB (CD137) (LALA-PG) | 1 mg | |||||
| Clone | LOB12.3-CP038 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo activation of 4-1BB* *Reported for the original rat IgG1 LOB12.3 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP039 | RecombiMAb anti-mouse 4-1BBL (CD137L) (D265A) | 1 mg | |||||
| Clone | TKS-1-CP039 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo 4-1BBL blockade*, ELISA* *Reported for the original rat IgG2a TKS-1 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP040 | RecombiMAb anti-mouse 4-1BBL (CD137L) | 1 mg | |||||
| Clone | TKS-1-CP040 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo 4-1BBL blockade*, ELISA* *Reported for the original rat IgG2a TKS-1 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP041 | RecombiMAb anti-mouse 4-1BBL (CD137L) (LALA-PG) | 1 mg | |||||
| Clone | TKS-1-CP041 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo 4-1BBL blockade*, ELISA* *Reported for the original rat IgG2a TKS-1 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP042 | RecombiMAb anti-mouse CD28 | 1 mg | |||||
| Clone | D665-CP042 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation* *Reported for the original mouse IgG1 D665 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP043 | RecombiMAb anti-mouse CD28 (LALA-PG) | 1 mg | |||||
| Clone | D665-CP043 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo T cell stimulation/activation*, in vitro T cell stimulation/activation* *Reported for the original mouse IgG1 D665 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP044 | RecombiMAb anti-mouse ICOSL (CD275) (D265A) | 1 mg | |||||
| Clone | HK5.3-CP044 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo ICOSL neutralization* *Reported for the original rat IgG2a HK5.3 antibody | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CP045 | RecombiMAb anti-mouse ICOSL (CD275) | 1 mg | |||||
| Clone | HK5.3-CP045 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo ICOSL neutralization* *Reported for the original rat IgG2a HK5.3 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP046 | RecombiMAb anti-mouse ICOSL (CD275) (LALA-PG) | 1 mg | |||||
| Clone | HK5.3-CP046 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo ICOSL neutralization* *Reported for the original rat IgG2a HK5.3 antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP047 | RecombiMAb mouse IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP048 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP049 | RecombiMAb mouse IgG2b (LALA-PG) isotype control, anti-hen egg lysozyme | 1 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP127 | RecombiMAb anti-mouse CD4 | 1/5/25/50/100 mg | |||||
| Clone | GK1.5-CP127 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo CD4+ T cell depletion*, Flow cytometry*, Western blot* *Reported for the original rat IgG2b GK1.5 antibody | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0065 | ||||||
| CP128 | RecombiMAb anti-mouse CD8α | 1/5/25/50/100 mg | |||||
| Clone | 2.43-CP128 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo CD8+ T cell depletion*, Western blot* *Reported for the original rat IgG2b 2.43 antibody | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0070 | ||||||
| CP129 | RecombiMAb anti-mouse Ly6G | 1/5/25/50/100 mg | |||||
| Clone | 1A8-CP129 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo neutrophil depletion*, in vivo MDSC depletion*, Immunofluorescence*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)*, Flow cytometry* *Reported for the original rat IgG2a 1A8 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP130 | RecombiMAb anti-mouse CD71 (TfR1) | 1/5/25/50/100 mg | |||||
| Clone | R17 217.1.3-CP130 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo depletion of CD71+ cells* *Reported for the original rat IgG2a R17 217.1.3 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP131 | RecombiMAb anti-mouse CSF1R (CD115) | 1/5/25/50/100 mg | |||||
| Clone | AFS98-CP131 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo macrophage depletion*, in vitro CSF1R neutralization*, in vivo monocyte depletion*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a AFS98 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP132 | RecombiMAb anti-mouse VEGFR-2 | 1/5/25/50/100 mg | |||||
| Clone | DC101-CP132 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of VEGF/VEGFR-2 signaling*, in vitro blocking of VEGFR signaling*, Western blot* *Reported for the original rat IgG1 DC101 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP133 | RecombiMAb anti-mouse CD40 | 1/5/25/50/100 mg | |||||
| Clone | FGK4.5-CP133 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD40 activation*, in vitro B cell stimulation/activation* *Reported for the original rat IgG2a FGK4.5 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP134 | RecombiMAb anti-mouse CD8α | 1/5/25/50/100 mg | |||||
| Clone | YTS 169.4-CP134 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo CD8+ T cell depletion*, Western blot* *Reported for the original rat IgG2b YTS 169.4 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP135 | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | 1/5/25/50/100 mg | |||||
| Clone | RB6-8C5-CP135 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)* *Reported for the original rat IgG2b RB6-8C5 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP146 | RecombiMAb anti-mouse CTLA-4 (CD152) | 1/5/25/50/100 mg | |||||
| Clone | 9H10-CP146 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo CTLA-4 neutralization*, in vitro CTLA-4 neutralization*, Western blot, *Reported for the original Syrian hamster IgG 9H10 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP147 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP148 | RecombiMAb human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP149 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP150 | RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP151 | RecombiMAb anti-mouse PD-1 (CD279) (D265A) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP151 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: CP150 Dilution Buffer: IP0070 | ||||||
| CP152 | RecombiMAb human IgG4 (S228P) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP152 | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP153 | RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP153 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: CP150 Dilution Buffer: IP0070 | ||||||
| CP154 | RecombiMAb anti-mouse PD-L1 (B7-H1) (LALA-PG) | 1/5/25/50/100 mg | |||||
| Clone | 10F.9G2™-CP154 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a 10F.9G2™ antibody | ||||||
| Recommended | Isotype Control: CP048 Dilution Buffer: IP0070 | ||||||
| CP155 | RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | 1/5/25/50/100 mg | |||||
| Clone | 29F.1A12™-CP155 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: CP156 Dilution Buffer: IP0070 | ||||||
| CP156 | RecombiMAb mouse IgG2a (LALA-PG) isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP156 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP157 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP157 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP158 | RecombiMAb anti-mouse PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | 10F.9G2™-CP158 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP159 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | 29F.1A12™-CP159 | Isotype | Mouse IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: BP0085 Dilution Buffer: IP0070 | ||||||
| CP160 | RecombiMAb mouse IgG2a isotype control, unknown specificity | 1/5/25/50/100 mg | |||||
| Clone | MOPC-21-CP160 | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP161 | RecombiMAb human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP161 | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP162 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP162 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP168 | RecombiMAb anti-mouse PD-L1 (B7-H1) | 1/5/25/50/100 mg | |||||
| Clone | 10F.9G2™-CP168 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo PD-L1 blockade*, Immunofluorescence*, Immunohistochemistry (frozen)*, Flow cytometry*, Western blot* *Reported for the original rat IgG2a RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP169 | RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus | 1/5/25/50/100 mg | |||||
| Clone | Palivizumab-CP169 | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP171 | RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP172 | RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) | 1/5/25/50/100 mg | |||||
| Clone | RB6-8C5-CP172 | Isotype | Mouse IgG2b, κ | ||||
| Application | in vivo depletion of Gr-1+ myeloid cells*, Flow cytometry*, Immunohistochemistry (paraffin)*, Immunohistochemistry (frozen)* *Reported for the original rat IgG2b RB6-8C5 antibody | ||||||
| Recommended | Isotype Control: BP0086 Dilution Buffer: IP0070 | ||||||
| CP173 | RecombiMAb human IgG1 (D265A) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP174 | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP175 | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP178 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | 29F.1A12™-CP178 | Isotype | Mouse IgG1, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling*, in vitro PD-1 neutralization*, Immunohistochemistry (frozen)*, Immunofluorescence*, Western blot*, Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody | ||||||
| Recommended | Isotype Control: BP0083 Dilution Buffer: IP0070 | ||||||
| CP179 | RecombiMAb HIS human IgG1 F(ab) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP180 | RecombiMAb human IgG2 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG2, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP181 | RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, λ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP182 | RecombiMAb anti-mouse PD-1 (CD279) | 1/5/25/50/100 mg | |||||
| Clone | RMP1-14-CP182 | Isotype | Rat IgG2a, κ | ||||
| Application | in vivo blocking of PD-1/PD-L signaling* *Reported for the original hybridoma expressed RMP1-14 antibody | ||||||
| Recommended | Isotype Control: BP0089 Dilution Buffer: IP0070 | ||||||
| CP183 | RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Human IgG4, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP186 | RecombiMAb Armenian hamster IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Armenian Hamster IgG1 | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP188 | RecombiMAb rat IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Rat IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP189 | RecombiMAb mouse IgG1 isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG1, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP190 | RecombiMAb mouse IgG2a isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2a, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CP191 | RecombiMAb mouse IgG2b isotype control, anti-hen egg lysozyme | 1/5/25/50/100 mg | |||||
| Clone | N/A | Isotype | Mouse IgG2b, κ | ||||
| Recommended | Dilution Buffer: IP0070 | ||||||
Recombinant Protein
| RP005 | Recombinant human EGF protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| Application | Cell culture (differentiation, maintenance/expansion), Organoid / 3D culture, Functional bioassay | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP006 | Recombinant human GDF-15 protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| Application | In vivo administration, Cell stimulation / signaling assay, Functional bioassay, Ex vivo tissue / explant culture | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP007 | Recombinant human FGF-2 (145 aa) protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Cell culture (differentiation, maintenance/expansion), Organoid / 3D culture, Functional bioassay | ||||||
| RP008 | Recombinant human R-spondin 3 protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Organoid / 3D culture, Cell culture (maintenance/expansion) | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP009 | Recombinant human noggin protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Organoid / 3D culture, Cell culture (differentiation, maintenance/expansion) | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP010 | Recombinant human LIF protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| Application | Cell culture (differentiation, maintenance/expansion), Embryo / embryo-model culture | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP011 | Recombinant human BMP-4 protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Cell culture (differentiation), Organoid / 3D culture | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP012 | Recombinant human KGF (FGF-7) protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Cell culture (differentiation), Organoid / 3D culture | ||||||
| RP013 | Recombinant human VEGF 165 protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Fish, Human | ||||||
| Application | Cell culture (differentiation), Functional bioassay, Organoid / 3D culture, Cell stimulation / signaling assay | ||||||
| RP014 | Recombinant human BDNF protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Cell culture (differentiation, maintenance/expansion), Organoid / 3D culture | ||||||
| RP015 | Recombinant human TGF-β3 protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Cell culture (maintenance/expansion) | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP016 | Recombinant human/mouse FGF-8b protein | 100/500/1,000 µg | |||||
| Reactivity | Human, Mouse | ||||||
| RP017 | Recombinant human NT-3 protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Cell culture (differentiation) | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP018 | Recombinant human FGF-8a protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| RP019 | Recombinant human activin E | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP020 | Recombinant human TGF-β2 protein | 100/500/1,000 µg | |||||
| Reactivity | Bovine, Human, Mouse, Rat | ||||||
| Application | Cell stimulation / signaling assay, Biophysical / structural | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP021 | Recombinant human G-CSF protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| RP022 | Recombinant human GM-CSF protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| RP023 | Recombinant human SCF protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| Application | Cell culture (differentiation, maintenance/expansion) | ||||||
| RP024 | Recombinant human TNF-alpha protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| RP025 | Recombinant human IL-2 protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| RP026 | Recombinant human IL-3 protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| Application | Cell culture (differentiation) | ||||||
| Recommended | Reconstitution Buffer: IP0010 | ||||||
| RP027 | Recombinant human IL-4 protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| Application | Cell culture (differentiation) | ||||||
| RP028 | Recombinant human IL-6 protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| RP029 | Recombinant human IL-7 protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| RP030 | Recombinant human IL-1β protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
| RP031 | Recombinant human IFN-gamma protein | 100/500/1,000 µg | |||||
| Reactivity | Human | ||||||
Bi-Tri-specific
| CPB501 | Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones RMP1-14 and 2G11-2A05 | Isotype | IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
| CPB502 | Bispecific anti-mouse CD3 x anti-mouse CD20 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 145-2C11 and MB20-11 | Isotype | IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB504 | Bispecific anti-mouse PD-1 x anti-mouse CTLA-4 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 9D9 and RMP1-14 | Isotype | IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB505 | Bispecific anti-mouse PD-1 x anti-mouse CTLA4 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones RMP1-14 and 9D9 | Isotype | Mouse IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
| CPB506 | Bispecific anti-mouse LAG3 x anti-mouse CTLA-4 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones C9B7W and 9D9 | Isotype | Mouse IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB510 | Bispecific anti-mouse PD-1 x anti-mouse PD-L1 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones RMP1-14 and 10F.9G2 | Isotype | IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
| CPB512 | Bispecific anti-mouse PD-L1 x anti-mouse CTLA-4 | 1/5/25 mg | |||||
| Clone | Derived from clones 10F.9G2 and 9D9 | Isotype | IgG2a-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Dilution Buffer: IP0070 | ||||||
| CPB513 | Bispecific anti-mouse LAG3 x anti-mouse PD-L1 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones C9B7W and 10F.9G2 | Isotype | IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
| CPB514 | Bispecific anti-mouse PD-L1 x anti-mouse VEGF (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 2G11-2A05 and 10F.9G2 | Isotype | Mouse IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
| CPB515 | Bispecific anti-mouse LAG3 x anti-mouse PD-1 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones C9B7W and RMP1-14 | Isotype | Mouse IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB519 | Bispecific anti-mouse CD3 x anti-mouse/human TRP1 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 145-2C11 and TA99 | Isotype | IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB520 | Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones B20-4.1.1 and 29F.1A12 | Isotype | Mouse IgG2a (LALA-PG)-scFv, κ | ||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
| CPB522 | Bispecific anti-mouse LAG3 x anti-mouse PD-1 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones C9B7W and 29F.1A12 | Isotype | IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB525 | Bispecific anti-mouse PD-L1 x anti-mouse 4-1BB (LALA-PG) | 1/5/25 mg | |||||
| Clone | 10F.9G2;LOB12.3;CPB525 | Isotype | IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB526 | Bispecific anti-mouse PD-1 x anti-mouse TIGIT (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 29F.1A12 and 1G9 | Isotype | IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB529 | Bispecific anti-mouse PD-1 x anti-mouse/human/rat/monkey ICOS (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 29F.1A12 and C398.4A | Isotype | IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB530 | Bispecific anti-mouse TL1A (TNFSF15) x anti-mouse IL23p19 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 5G4.6 and G23-8 | Isotype | IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB531 | Bispecific anti-mouse IL17A x anti-mouse IL17F | 1/5/25 mg | |||||
| Clone | Derived from clones 17F3 and MM17F8F5.1A9 | Isotype | IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
| CPB532 | Bispecific anti-mouse TIGIT x anti-mouse CD25 (IL-2Rα) | 1/5/25 mg | |||||
| Clone | Derived from clones 1G9 and 7D4 | Isotype | IgG2a, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CP160 Dilution Buffer: IP0070 | ||||||
| CPB536 | Trispecific anti-mouse PD-L1× anti-mouse TIGIT× anti-mouse LAG3 | 1/5/25 mg | |||||
| Clone | Derived from clones 1G9, C9B7W, 10F.9G2 | Isotype | IgG2a-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB509 Dilution Buffer: IP0070 | ||||||
| CPB537 | Bispecific anti-mouse CD3 x anti-mouse CD19 (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones 145-2C11 and 1D3 | Isotype | IgG2a (LALA-PG), κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB503 Dilution Buffer: IP0070 | ||||||
| CPB538 | Bispecific anti-mouse CD3 x anti-mouse/human BCMA (D265A) | 1/5/25 mg | |||||
| Clone | Derived from clones 145-2C11 and Ab-2 | Isotype | IgG1 (D265A) | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CP047 Dilution Buffer: IP0070 | ||||||
| CPB545 | Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) | 1/5/25 mg | |||||
| Clone | Derived from clones RMP1-14 and B20-4.1.1 | Isotype | IgG2a (LALA-PG)-scFv, κ | ||||
| Application | ELISA, For information on in vivo applications, please contact technicalservice@bioxcell.com | ||||||
| Recommended | Isotype Control: CPB500 Dilution Buffer: IP0070 | ||||||
パンフレット

Cancer
癌研究用の抗体

Immunology
免疫学研究用の抗体

Neuroscience
神経科学研究用の抗体

Biosimilars
研究用グレードのバイオシミラーモノクローナル抗体

Depletion Antibodies
マウス免疫細胞を特異的に除去する抗体

Cytokine and Chemokines
サイトカインとそのレセプターを中和・検出する抗体

CD Markers
CDマーカーを標的とする抗体

Tumor Specific Antigens
腫瘍特異的抗原を標的とする抗体

Cell Adhesion and Migration
細胞遊走や細胞接着に関わるタンパク質をブロッキング・検出する抗体

25-Year Anniversary Brochure
Bio X Cell社の全般情報に関するパンフレット
ウェビナー
Bio X Cell 公式ウェビナーを見る(無料)各商品の価格のお問合せ、商品仕様書のご依頼、その他のお問い合わせは下記までお願いします。
【商品取扱元】株式会社 東京未来スタイル
info@tokyofuturestyle.com
TEL:029-851-9222 FAX:029-851-9220















